In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Kaitlin Christenson, director of the GHTC, summarizes news out of the
World Health Assembly (WHA) impacting the global health research and development (R&D) community including debates on the post-Consultative Expert
Working Group on Research and Development: Financing and Coordination and post-2015 development agenda, and themes related to regulatory system strengthening,
access to essential medicines, and the value of R&D.
Renate Baehr—executive director of Deutsche Stiftung Weltbevoelkerung—writes about the next rendition of the European & Developing Countries Clinical Trials Partnership and how its expansion will impact more lives in low-
and middle-income countries. She discusses how the program has been broadened to include neglected tropical diseases and how African countries will
now fully participate in the group’s governance and decision making.
The Canadian government announced it would provide $12 million
to Grand Challenges Canada to finance innovations to improve maternal and child health in the developing world. The funding will support 65 projects
to be implemented across 25 low-and middle-income countries. The announcement came in advance of the Canadian Prime Minister’s global summit on maternal,
newborn, and child health taking place in Toronto from May 28-30.
Wired reports on the passage of a resolution at WHA to create a global action plan
to tackle the emerging problem of antibiotic resistance that will include exploring technology innovations in diagnostic testing and new drug development.
The article notes that some experts believe this will not do enough to stem the problem and are calling for the creation of an intergovernmental body
on antibiotic resistance that would be similar to the Intergovernmental Panel on Climate Change.